



12-29-03

Patent Docket P1245R1P2BC1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of</p> <p>Avi Ashkenazi et al.</p> <p>Serial No.: 10/660,128</p> <p>Filed: September 11, 2003</p> <p>For: DR4 Antibodies and Uses Thereof</p>	<p>Group Art Unit: to be assigned</p> <p>Examiner: to be assigned</p> <p>Customer No: 09157</p>
	<p>CERTIFICATE OF EXPRESS MAILING</p> <p>Express Mail Number: <u>EV 351 928 645 US</u></p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450".</p> <p>December <u>24</u>, 2003</p> <p><u>Diane L. Marschang</u></p> <p>Diane L. Marschang</p>

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449 with 12 References;
3. Return postcard.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.


Respectfully submitted,

GENENTECH, INC.

Date: December 24, 2003


By: Diane L. Marschang
Diane L. Marschang
Reg. No. 35,600
Telephone No. (650) 225-5416

#144794



Patent Docket P1245R1P2BC1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of Avi Ashkenazi et al. Serial No.: 10/660,128 Filed: September 11, 2003 For: DR4 Antibodies and Uses Thereof</p>	<p>Group Art Unit: to be assigned Examiner: to be assigned CUSTOMER NO: 09157</p> <hr/> <p>CERTIFICATE OF EXPRESS MAILING Express Mail Number: <u>EV 351 928 645 US</u> I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450". December <u>24</u>, 2003  Diane L. Marschang</p>
--	--

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[X] **37 CFR § 1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR § 1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR § 1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR § 1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) **or** a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) **and** a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patents or publications is set forth on the attached revised Form PTO-1449 (Modified). A copy of item numbers 1, 2, 3, 4, 7, 11, 13, 14, 15, 39, 57 and 64 on PTO-1449 is supplied herewith. Those patents or publications which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 09/584,166, filed 25 May 2000 and relied upon in this application for an earlier filing date under 35 USC §120.

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-()" (nucleotide) and "BLAST Results B-1 - B-()" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.


In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

By: 
Diane L. Marschang
Reg. No. 35,600
Telephone No. (650) 225-5416

Date: December 24, 2003

#144787

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1245R1P2BC1

Serial No.

10/660128

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

11 Sep 2003

Group

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	1	2003/0036168	20.02.03	Ni et al.			
	2	2003/0073187	17.04.03	Ni et al.			
	3	2003/0108516	12.06.03	Ni et al.			
	4	2003/0133932	17.07.03	Zhou et al.			
	* 5	5,763,223	09.06.98	Wiley et al.			
	* 6	6,342,363 B1	29.01.02	Ni et al.			
	7	6,429,186	06.08.02	Fuh et al.			
	* 8	6,433,147	13.08.02	J. Ni et al.			
	* 9	6,461,823	08.10.02	Ni et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
	* 10	WO 00/67793	16.11.00	PCT			
	11	WO 02/094880	28.11.02	PCT			
	* 12	WO 02/097033	05.12.02	PCT			
	13	WO 03/037913	08.05.03	PCT			
	14	WO 03/038043	08.05.03	PCT			
	15	WO 03/042367	22.05.03	PCT			
	* 16	WO 92/15698	17.09.92	PCT			
	* 17	WO 97/01633	16.01.97	PCT			
	* 18	WO 97/25428	17.07.97	PCT			
	* 19	WO 98/32856	30.07.98	PCT			
	* 20	WO 98/51793	19.11.98	PCT			
	* 21	WO 99/37684	29.07.99	PCT			
	* 22	WO 99/64461	16.12.99	PCT			
	* 23	02/079377	10.10.02	WO			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	* 24	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-Induced Death of Developing T Cells" <u>Symposium on Programmed Cell Death</u> (Abstract No. 10), Cold Spring Harbor Laboratory (1995)
	* 25	Armitage et al., "Molecular and Biological Characterization of a Murine Ligand for CD40." <u>Nature</u> , 357(6373):80-82 (1992)
	* 26	Aruffo et al., "CD44 is the Principal Cell Surface Receptor for Hyaluronate" <u>Cell</u> 61:1303-1313 (1990)
	* 27	Ashkenazi and Dixit, "Apoptosis control by death and decoy receptors" <u>Current Opinion in Cell Biology</u> 11(2):255-260 (1999)
	* 28	Ashkenazi, A., "Apoptosis regulation by death and decoy receptors" <u>FASEB Journal</u> (Annual Meeting of the American Societies for Experimental Biology on Biochemistry and Molecular Biology) 13(7):A1336 (1999)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1245R1P2BC1

Serial No.

10/660128

Applicant

Ashkenazi et al.

Filing Date

11 Sep 2003

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 29	Baldwin, A., "The NF- κ B and I κ B Proteins: New Discoveries and Insights" <u>Ann. Rev. Immunol.</u> 14:649-683 (1996)
* 30	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
* 31	Barr and Tomei, "Apoptosis and Its Role in Human Disease" <u>Bio/Technology</u> 12:487-493 (1994)
* 32	Blake et al., "Metal binding properties of a monoclonal antibody directed toward metal-chelate complexes" <u>Journal of Biological Chemistry</u> 271(44):27677-27685 (Nov 1, 1996)
* 33	Bodmer et al., "TRAMP, A Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)." <u>Immunity</u> 6:79-88 (1997)
* 34	Boldin et al., "Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death" <u>Cell</u> 85:803-815 (1996)
* 35	Boldin et al., "Self-Association of the "Death Domains" of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects" <u>Journal of Biological Chemistry</u> 270:387-391 (1995)
* 36	Brockhaus et al., "Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies." <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)
* 37	Brojatsch et al., "CAR1, A TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis." <u>Cell</u> 87:845-855 (1996)
* 46	Browning et al., "Lymphotoxin β , a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface" <u>Cell</u> 72:847-856 (1993)
39	Campbell, A., "General Properties and applications of monoclonal antibodies" <u>Monoclonal Antibody Technology</u> , The Netherlands:Elsevier Science Publishers B.V., Chapter 1, pps. 1-32 (1984)
* 40	Carter et al., "Humanization of an Anti-p185HER2 Antibody For Human Cancer Therapy" <u>Proc. Natl. Acad. Sci. USA</u> 89:4285-4289 (May 1992)
* 41	Chaudhary et al., "Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF- κ B Pathway" <u>Immunity</u> 7:821-830 (1997)
* 42	Chinnaiyan and Dixit, "The Cell-Death Machine" <u>Current Biology</u> 6:555-562 (1996)
* 43	Chinnaiyan et al., "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis" <u>Cell</u> 81:505-512 (1995)
* 44	Chinnaiyan et al., "FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis" <u>Journal of Biological Chemistry</u> 271:4961-4965 (1996)
* 45	Chinnaiyan et al., "Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death" <u>Science</u> 275:1122-1126 (1997)
* 46	Chinnaiyan et al., "Signal Transduction by DR3, A Death Domain-Containing Receptor Related to TNFR-1 and CD95." <u>Science</u> 274:990-992 (1996)
* 47	Chuntharapai et al., "The induction and blocking of apoptosis by anti Apo2 monoclonal antibodies" <u>FASEB Journal</u> (Annual Meeting of the Professional Research Scientists for Experimental Biology) 13(4):A518 (1999)
* 48	Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" <u>Cell</u> 81:479-482 (1995)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DEC 24 2003

Sheet 3 of 6

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1245R1P2BC1

Serial No.

10/660128

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

11 Sep 2003

Group


OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 49	Craig et al., "The role of structure in antibody cross-reactivity between peptides and folded proteins" <u>Journal of Molecular Biology</u> 281(1):183-201 (Aug 7, 1998)
* 50	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon- γ " <u>European Journal of Immunology</u> 17:689-693 (1987)
* 51	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1170 (1997)
* 52	Enari et al., "Involvement of an ICE-like protease in Fas-mediated Apoptosis" <u>Nature</u> 375:78-81 (1995)
* 53	Engberg et al. <u>Antibody Engineering Protocols</u> pps. 375 (1995)
* 54	Fraser and Evan, "A License to Kill" <u>Cell</u> 85:781-784 (1996)
* 55	Goodwin et al., "Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor." <u>Mol. Cell. Bio.</u> 11:3020-3026 (1991)
* 56	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)
57	Gussow & Seemann, "Humanization of Monoclonal Antibodies" <u>Meth. Enzymology</u> , Academic Press, Inc. Vol. 203:99-121 (1991)
* 58	Gussow et al., "Humanization of Monoclonal Antibodies" <u>Methods in Enzymology/Humanization of Monoclonal Antibodies</u> 203:99-117
* 59	Hale et al., "Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed in E. coli." <u>J. Cell. Biochem.</u> (abstract only, suppl. 15F; P 424) pps. 113 (1991)
* 60	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF α)" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)
* 61	Hsu et al., "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways" <u>Cell</u> 84:299-308 (1996)
* 62	Itoh et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis." <u>Cell</u> 66:233-243 (1991)
* 63	Janeway et al. <u>Immunobiology</u> , 3rd edition (1997)
64	Janeway et al. <u>Immunobiology</u> , Garland Press London and NY Vol. 4th Edition:544 (1997)
* 65	Jo et al., "Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand" <u>Nature Medicine</u> 6(5):564-567 (2000)
* 66	Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986)
* 67	Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996)
* 68	Kohno et al., "A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor." <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1245R1P2BC1	Serial No. 10/660128
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Ashkenazi et al.	
				Filing Date 11 Sep 2003	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	* 69	Kortt et al., "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer" <u>Protein Engineering</u> 10(4):423-433 (Apr 1997)			
	* 70	Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994)			
	* 71	Lewis et al., "Cloning and Expression of cDNAs for Two Distinct Murine Tumor Necrosis Factor Receptors Demonstrate One Receptor is Species Specific." <u>PNAS USA</u> , 88:2830-2834 (1991)			
	* 72	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990)			
	* 73	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (1997)			
	* 74	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)			
	* 75	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain" <u>Current Biology</u> 7:1003-1006 (1997)			
	* 76	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA." <u>Current Biology</u> , 6(6):750-752 (1996)			
	* 77	Marsters et al., "Apo-3, A New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- κ B." <u>Curr. Biol.</u> 6(12):1669-1676 (1996)			
	* 78	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor Receptor (TNFR) Family, Interacts with Members of the TNFR-Associated Factor Family and Activates the Transcription Factors NF- κ B and AP-1." <u>J. Bio. Chem.</u> 272(22):14029-14032 (1997)			
	* 79	Mongkolsapaya et al., "Cutting Edge: Lymphocyte Inhibitor of TRAIL (TNF-Related Apoptosis-Inducing Ligand): A New Receptor Protecting Lymphocytes From the Death Ligand TRAIL." <u>J. Immunol.</u> 160(1):3-6 (1998)			
	* 80	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)			
	* 81	Moore et al., "Simultaneous measurement of cell cycle and apoptotic cell death" <u>Methods in Cell Biology</u> , Chapter 15, 57:265-278 (1998)			
	* 82	Muzio et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex" <u>Cell</u> 85:817-827 (1996)			
	* 83	Nagata and Golstein, "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995)			
	* 84	Nagata, S., "Apoptosis by Death Factor." <u>Cell</u> , 88:355-365 (Feb 1997)			
	* 85	Nophar et al., "Soluble Forms of Tumor Necrosis Factor Receptors (TNF-Rs). The cDNA for the Type I TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble Form, Encodes Both the Cell Surface and a Soluble Form of the Receptor." <u>EMBO Journal</u> , 9:3269-3278 (1990)			
	* 86	Pan et al., "An Antagonist Decoy Receptor and a Death-Domain Containing Receptor for TRAIL." <u>Science</u> , 277:815-818 (Aug 1997)			
	* 87	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL." <u>Science</u> , 276:111-113 (Apr 4, 1997)			
	* 88	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>European Journal of Haematology</u> 41:414-419 (1988)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1245R1P2BC1

Serial No.

10/660128

Applicant

Ashkenazi et al.

Filing Date

11 Sep 2003

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 89	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
* 90	Radeke et al., "Gene Transfer and Molecular Cloning of the Rat Nerve Growth Factor Receptor." <u>Nature</u> . 325:593-597 (1987)
* 91	Raff, "Social Controls on Cell Survival and Cell Death" <u>Nature</u> 356:397-400 (1992)
* 92	Ray et al., "Viral Inhibition of Inflammation: Cowpox Virus Encodes an Inhibitor of the Interleukin-1 β Converting Enzyme" <u>Cell</u> 69:597-604 (May 15, 1992)
* 93	Sachs et al., "Control of Programmed Cell Death in Normal and Leukemic Cells: New Implications for Therapy" <u>Blood</u> 82:15-21 (1993)
* 94	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990)
* 95	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruct. Mediated by Cytotoxic T-cell Lines, Lymphotoxin-Secreting Helper T-cell Clones, and Cell-Free Lymphotoxin-Containing Supernatant." <u>PNAS USA</u> . 83:1881-1885 (1986)
* 96	Schneider et al., "Characterization of Two Receptors for TRAIL." <u>FEBS Letters</u> . 416:329-334 (1997)
* 97	Schneider et al., "TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF- κ B" <u>Immunity</u> 7(6):831-836 (Dec 1997)
* 98	Screaton et al., "TRICK2, A New Alternatively Spliced Receptor that Transduces the Cytotoxic Signal From TRAIL." <u>Current Biology</u> . 7:693-696 (1997)
* 99	Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor α Inhibitor" <u>Journal of Biological Chemistry</u> 264:11966-11973 (1989)
*100	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
*101	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997)
*102	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (1990)
*103	Smith et al., "T2 Open Reading Frame From the Shope Fibroma Virus Encodes a Soluble Form of the TNF Receptor." <u>Biochem. & Biophys. Res. Comm.</u> 176:335-342 (1991)
*104	Song et al., "Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression" <u>Journal of Experimental Medicine</u> 191(7):1095-1103 (2000)
*105	Stamenkovic et al., "A B-Lymphocyte Activation Molecule Related to the Nerve Growth Factor Receptor and Induced by Cytokines in Carcinomas." <u>EMBO Journal</u> . 8(5):1403-1410 (1989)
*106	Steller, H., "Mechanisms and Genes of Cellular Suicide" <u>Science</u> 267:1445-1449 (1995)
*107	Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" <u>Immunogenetics</u> 37:199-203 (1993)
*108	Tartaglia et al., "A novel domain within the 55 kd TNF receptor signals cell death" <u>Cell</u> 74(5):845-853 (1993)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DEC 24 2003

Sheet 6 of 6

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1245R1P2BC1

Serial No.

10/660128

Applicant

Ashkenazi et al.

Filing Date

11 Sep 2003

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*109	Tewari and Dixit, "Fas- and Tumor Necrosis Factor-induced Apoptosis Is Inhibited by the Poxvirus crmA Gene Product" <u>Journal of Biological Chemistry</u> 270:3255-3260 (1995)
*110	Tewari and Dixit, "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" <u>Curr. Op. Genet. Develop.</u> 6:39-44 (1996)
*111	Tewari et al., "Yama/CPP32 β , a Mammalian Homolog of CED-3, Is a CrmA-Inhibitible Protease That Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase" <u>Cell</u> 81:801-809 (1995)
*112	Thompson, "Apoptosis in the Pathogenesis and Treatment of Disease" <u>Science</u> 267:1456-1462 (1995)
*113	Upton et al., "Myxoma Virus Expresses a Secreted Protein with Homology to the Tumor Necrosis Factor Receptor Gene Family that Contributes to Viral Virulence." <u>Virology</u> 184:370-382 (1991)
*114	Upton et al., "Tumorigenic Poxviruses: Genomic Organization and DNA Sequence of the Telomeric Region of the Shope Fibroma Virus Genome." <u>Virology</u> 160:20-30 (1987)
*115	Verma et al., "Rel/NF-KB/IkB Family: Intimate Tales of Association and Dissociation" <u>Genes Develop.</u> 9:2723-2735 (1995)
*116	von Bulow and Bram, "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily" <u>Science</u> 278:138-141 (1997)
*117	Walczak et al., "TRAIL-R2: A Novel Apoptosis-Mediating Receptor for TRAIL." <u>EMBO Journal</u> 16(17):5386-5397 (1997)
*118	Watanabe-Fukunaga et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis" <u>Nature</u> 356:314-317 (1992)
*119	Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" <u>Proc. Natl. Acad. Sci. USA</u> 88:159-163 (1991)
*120	Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995)
*121	Wong et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells." <u>J. Bio. Chem.</u> 272(40):25190-25194 (Oct 3, 1997)
*122	Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding" <u>Journal of Biological Chemistry</u> 266:12099-12104 (1991)
*123	Yonehara et al., "A Cell-Killing Monoclonal Antibody (Anti-Fas) to a Cell Surface Antigen Co-Downregulated with the Receptor of Tumor Necrosis Factor." <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989)
*124	Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" <u>Nature</u> 377:348-351 (1995)
*125	Zou et al., "Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c-Dependent Activation of Caspase-3" <u>Cell</u> 90:405-413 (1997)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.